INmune Bio, Inc. (INMB)

Market Cap	193.32M
Revenue (ttm)	155,000
Net Income (ttm)	-30.01M
Shares Out	18.20M
EPS (ttm)	-1.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	114,528
Open	10.32
Previous Close	10.14
Day's Range	9.88 - 10.73
52-Week Range	6.50 - 14.74
Beta	1.95
Analysts	Buy
Price Target	16.00 (+50.66%)
Earnings Date	May 1, 2024

About INMB

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2019
• Employees: 11
• Stock Exchange: NASDAQ
• Ticker Symbol: INMB

Financial Performance

In 2023, INmune Bio's revenue was $155,000, a decrease of -58.56% compared to the previous year's $374,000. Losses were -$30.01 million, 9.92% more than in 2022.

Analyst Forecast

According to one analyst, the rating for INMB stock is "Buy" and the 12-month stock price forecast is $16.0.

Price Target

$16.0

(50.66% upside)

Analyst Consensus: Buy